Roche is acquiring PathAI, a digital pathology and AI-powered technology company, to enhance its digital pathology capabilities. This merger builds on a successful partnership established in 2021, focusing on AI-enabled companion diagnostics. The acquisition will integrate PathAI's technology, including its advanced Image Management System (IMS), within Roche's Diagnostics division. This integration aims to streamline laboratory workflows and accelerate the shift toward personalized healthcare. The collaboration seeks to enhance precision diagnosis of cancer and improve treatment regimens for patients. PathAI's AI-driven solutions will complement Roche's expertise in companion diagnostics, boosting biopharma services. This will foster the discovery of new biomarkers and novel diagnostic tools, increasing Roche's value to biopharma companies. The deal involves an upfront payment of USD 750 million plus potential milestone payments up to USD 300 million. This acquisition will expand Roche's global reach in the rapidly growing digital pathology market.